Adherence to hospital discharge medication in patients with ischemic stroke: A prospective, interventional 2-phase study

Stroke

Volumn 44, Issue 2, 2013, Pages 522-524

  Hohmann, Carina ^a   Neumann Haefelin, Tobias ^a   Klotz, Jürgen M ^a   Freidank, Annette ^a   Radziwill, Roland ^a  

^a KLINIKUM FULDA   (Germany)

Author keywords

adherence; hospital discharge medication; ischemic stroke; secondary prevention

Indexed keywords

ANTICOAGULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; EARLY MEDICAL INTERVENTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT DISCHARGE; PHARMACISTS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; STROKE;

EID: 84872977032     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.678847     Document Type: Article

References (11)

1. Midlöv P, Bergkvist A, Bondesson A, Eriksson T, Höglund P. Medication errors when transferring elderly patients between primary health care and hospital care. Pharm World Sci. 2005;27:116-120.
2. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. J Hosp Med. 2007;2:314-323.
3. Karapinar F, van den Bemt PM, Zoer J, Nijpels G, Borgsteede SD. Informational needs of general practitioners regarding discharge medication: content, timing and pharmacotherapeutic advice. Pharm World Sci. 2010;32:172-178.
4. Himmel W, Tabache M, Kochen MM. What happens to long-term medication when general practice patients are referred to hospital? Eur J Clin Pharmacol. 1996;50:253-257.
5. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-276.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
7. Heart Protection Study Collaborative Group. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;263:757-767.
8. Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397-401.
9. Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001;32:1884-1889.
10. Bushnell CD, Zimmer LO, Pan W, Olson DM, Zhao X, Meteleva T, et al Adherence Evaluation After Ischemic Stroke-Longitudinal Investigators. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol. 2010;67:1456-1463.
11. Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CD. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke. 2000;31:469-475.